Compare Mesoblast Limited (MESO) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Simon Property Group Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Simon Property Group Inc trades at $226.36 (market cap $74.00B). The key difference: Simon Property Group Inc is far larger — about 34.1× Mesoblast Limited's market cap, and Simon Property Group Inc pays a 3.86% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SPG | |
|---|---|---|
Market Cap | $2.17B | $74.00B |
Sector | Technology | Real Estate |
52-Week High | $20.96 | $228.70 |
52-Week Low | $12.88 | $160.68 |
Enterprise Value | $2.17B | $102.48B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SPG trades at $228.53, down 0.07% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.48 versus $1.46, maintaining a three-quarter beat streak. Revenue growth continues from $6.0B in 2024 to $6.4B in 2025, supported by strong leasing activity and portfolio redevelopment. The stock offers a 4% dividend yield with recent H1-26 payment of $2.25 declared.
SPG presents a compelling investment case with strong operational performance and upward earnings revisions, though elevated valuation metrics and significant long-term debt of $24.21B warrant caution. Analyst consensus leans positive with 40.5% buy ratings but mixed sentiment reflects concerns about e-commerce competition and interest rate sensitivity. The current price sits above the $214.40 consensus target, suggesting limited near-term upside potential despite solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
